The organic constant currency growth of 6.7% and raised adjusted EPS guidance suggest underlying business momentum, but reported revenue decline and domestic weakness warrant monitoring. Watch for further details on the AirSeal robotic indication ramp and international growth trajectory on the conference call.
Price Chart
Executive Summary
CONMED reported Q3 2026 adjusted EPS of $1.04, above the $1.00 consensus, while GAAP revenue of $335.6M slightly missed the $336.3M estimate. Reported revenue declined 0.7% YoY, but organic constant currency revenue grew 6.7%, driven by balanced Orthopedic and General Surgery growth. Full-year 2026 adjusted EPS guidance was raised to $4.54-$4.61 from $4.48-$4.60, while organic constant currency revenue growth guidance was narrowed to 5.0%-5.5% from 5.0%-6.0%.
Key Financial Metrics
Key Facts
- Q3 2026 GAAP revenue $335.6M, down 0.7% YoY as reported, but organic constant currency revenue up 6.7%
- Adjusted diluted EPS $1.04, down 3.2% YoY, versus consensus of $1.00
- GAAP diluted EPS $0.66, up from $0.09 in Q3 2025
- Domestic sales declined 11.0% as reported, but grew 0.8% on an organic basis
- International sales grew 13.1% as reported and 13.8% on an organic constant currency basis
- Full-year 2026 adjusted EPS guidance raised to $4.54-$4.61 from $4.48-$4.60
- Full-year 2026 organic constant currency revenue growth guidance narrowed to 5.0%-5.5% from 5.0%-6.0%
- GAAP revenue guidance narrowed to $1.360B-$1.366B from $1.358B-$1.373B
- AirSeal Robotic Solution now indicated for use with Intuitive da Vinci 5 platform (announced July 22, 2026)
Financial Impact
Adjusted EPS beat consensus by $0.04 (4.0%), revenue miss of $0.7M (0.2%)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Orthopedic Surgery | $148.8M | +7.7% |
| General Surgery | $186.7M | -6.5% |
Risk Factors
- Domestic sales declined 11.0% as reported, signaling potential market share or demand issues in the US
- Adjusted EPS declined 3.2% YoY despite the beat, indicating margin pressure
- Interest expense rose to $11.1M from $7.6M in Q3 2025, increasing financial leverage
- Full-year organic constant currency revenue guidance narrowed at the lower end (5.0% vs prior 5.0% low), suggesting tempered growth expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000816956-26-000110 |
| Document: cnmd-20261028.htm | 0000816956-26-000110 |
| Document: 0000816956-26-000110-index-headers.html | 0000816956-26-000110 |
| Document: 0000816956-26-000110-index.html | 0000816956-26-000110 |
| Document: 0000816956-26-000110.txt | 0000816956-26-000110 |
| 8-K Data (Synthetic) | 0000816956-26-000110 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 2d ago | 8-K | $45.72 | awaiting T+20 | awaiting T+20 | $44.29 (−3.13%) |
Jun 17, 2026 19w ago | 8-K | $32.58 $45.01 | ▲ +38.15% | ▲ +37.62% | $44.29 (+35.94%) |
Jun 1, 2026 21w ago | 8-K | $34.65 $32.73 | ▼ −5.54% | ▼ −4.24% | $44.29 (+27.82%) |
May 20, 2026 23w ago | 8-K | $37.01 $32.58 | ▼ −11.97% | ▼ −12.71% | $44.29 (+19.67%) |
Apr 7, 2026 29w ago | DEFA14A | $34.54 $35.88 | ▲ +3.88% | ▼ −5.90% | $44.29 (+28.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers